Evidence map›Paper›PMID 42702702›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Clinical outcomes of teicoplanin for Corynebacterium species bacteremia: A retrospective observational study.

Mitsutaka Kimura, Takaaki Yamada, Shigeki Nemoto, Yukari Inada, Masaya Morimoto, Takayuki Nakagawa, Yusuke Koizumi

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mitsutaka KimuraDepartment of Clinical Infectious Diseases, Infection Control and Prevention, Wakayama Medical University, Wakayama, 641-8509, Japan.
Takaaki YamadaDepartment of Clinical Pharmacology and Therapeutics, School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama, 640-8156, Japan.
Shigeki NemotoDepartment of Clinical Infectious Diseases, Infection Control and Prevention, Wakayama Medical University, Wakayama, 641-8509, Japan.
Yukari InadaDepartment of Clinical Infectious Diseases, Infection Control and Prevention, Wakayama Medical University, Wakayama, 641-8509, Japan.
Masaya MorimotoDepartment of Clinical Infectious Diseases, Infection Control and Prevention, Wakayama Medical University, Wakayama, 641-8509, Japan.
Takayuki NakagawaDepartment of Pharmacy, Wakayama Medical University Hospital, Wakayama, 641-8509, Japan.
Yusuke KoizumiDepartment of Clinical Infectious Diseases, Infection Control and Prevention, Wakayama Medical University, Wakayama, 641-8509, Japan. ykoizumi@wakayama-med.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeVancomycin (VCM) is commonly used as targeted therapy for Corynebacterium species bacteremia. Although teicoplanin (TEIC) is considered a potential alternative, clinical evidence supporting its use remains limited because of the small number of reported cases. This study evaluated the clinical effectiveness and safety of TEIC compared with VCM for the treatment of Corynebacterium species bacteremia.

methodsWe conducted a retrospective observational study of patients with Corynebacterium species bacteremia who received either VCM (n = 25) or TEIC (n = 14) between January 2014 and December 2025. The primary outcome was clinical success at the end of therapy. Secondary outcomes included microbiological success and safety.

resultsClinical success rates were high in both groups (VCM, 78.3%; TEIC, 81.8%), and microbiological success was achieved in nearly all patients. The TEIC group consisted predominantly of immunocompromised patients with hematological malignancies. Despite these high-risk clinical characteristics, TEIC showed favorable clinical effectiveness and safety.

conclusionTEIC may represent a reasonable treatment option for Corynebacterium species bacteremia. Favorable outcomes were observed even among immunocompromised patients with hematological malignancies.

Indexed as

BacteremiaCorynebacteriumTeicoplaninVancomycin

Identifiers

PMID42702702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.